Pousette A, Björk P, Carlström K, Forsgren B, Högberg B, Gustafsson J A
Prostate. 1981;2(1):23-33. doi: 10.1002/pros.2990020104.
Prostatic secretion protein (PSP) is a major component of rat prostatic cytosol, and this protein is also found in the prostatic fluid. Purified PSP was found to inhibit the nuclear uptake of the [3H]methyltrienolone-receptor complex in vitro. Furthermore, purified PSP inhibited the binding of this androgen-receptor complex to DNA-cellulose. It is suggested that these effects of PSP may represent an intracellular control system regulating the concentration of PSP. Administration of estramustine, the dephosphorylated metabolite of the anti-cancer drug estramustine phosphate (Estracyt), to rats was found to decrease the weight of the prostate gland but to maintain the concentration of PSP, calculated as mg PSP/mg protein, at a constant level. In contrast, castration or administration of estradiol-17 beta valerate decreased the weight of the prostate gland as well as the concentration of PSP. These findings indicate that the mechanism of action of estramustine is at least partially different from that of estradiol-17 beta. Furthermore, it is suggested that estramustine may exert part of its action through its effects on the concentration of PSP.
前列腺分泌蛋白（PSP）是大鼠前列腺胞质溶胶的主要成分，这种蛋白在前列腺液中也能找到。研究发现，纯化后的PSP在体外可抑制[3H]甲基三烯olone-受体复合物的核摄取。此外，纯化后的PSP可抑制这种雄激素-受体复合物与DNA纤维素的结合。有人认为，PSP的这些作用可能代表了一种调节PSP浓度的细胞内控制系统。研究发现，给大鼠施用雌莫司汀（抗癌药物磷酸雌莫司汀（癌腺治）的去磷酸化代谢产物）会使前列腺重量减轻，但以mg PSP/mg蛋白质计算的PSP浓度会维持在恒定水平。相比之下，去势或施用戊酸雌二醇-17β会使前列腺重量以及PSP浓度降低。这些发现表明，雌莫司汀的作用机制至少部分不同于雌二醇-17β。此外，有人认为雌莫司汀可能通过其对PSP浓度的影响发挥部分作用。
